Navigation Links
Clinical Experts Detail How They Use Varian's TrueBeam™ Technology to Improve the Precision and Speed of Cancer Treatments
Date:9/14/2010

inappropriate because of her age and an earlier operation. She received eight stereotactic body radiosurgery treatments over a two-week period using TrueBeam in combination with RapidArc® technology and Professor Slotman described this pioneering treatment.

Professor Slotman also outlined key findings from two years of RapidArc radiotherapy treatments for more than 1,000 patients at VU, almost of third of them receiving hypo-fractionated, stereotactic body radiotherapy. "Delivering treatments rapidly is especially important when you need to deliver high doses with great precision, as shortening treatment times considerably reduces the extent of patient motion during treatment," he said.  

During a presentation on "Emerging Clinical Applications in Radiosurgery", Dr. John Adler, Varian's chief of new clinical applications, spoke about the use of hypo-fractionation for a range of cancers as well as other lesions, tumors and conditions where radiosurgery may be indicated.

TrueBeam

Designed to advance the treatment of lung, breast, prostate, head and neck, and other types of cancer, Varian's TrueBeam platform for image-guided radiotherapy and radiosurgery as introduced in April as the first fully-integrated system designed from the ground up to treat a moving target with unprecedented speed and accuracy.

Applicable for all forms of advanced external-beam radiotherapy including image-guided radiotherapy and radiosurgery (IGRT and IGRS), intensity-modulated radiotherapy (IMRT), stereotactic body radiotherapy (SBRT) and RapidArc® radiotherapy, TrueBeam can deliver treatments with a dose delivery rate of up to 2400 monitor units per minute, double the maximum output of conventional systems. This makes it possible to offer greater patient comfort by shortening treatments, and to improve precision by leaving less time for tumor motion during dose delivery.  

Editorial contact: Neil Madle, Varian Medical Sy
'/>"/>

SOURCE Varian Medical Systems, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Oramed Pharmaceuticals Announces Successful Results of a Novel Exploratory Clinical Study of its Flagship Oral Insulin Capsule
2. First Patient Enrolled in CONNECT Clinical Trial
3. Reportlinker Adds Clinical Trials in China
4. Purdue Pharma L.P. to Present Data From Clinical Program for Butrans™ (buprenorphine) Transdermal System CIII at PAINWeek® 2010
5. Stereotaxis Announces First-Ever, Prospective, Comparative Clinical Trial Outcome for VT Patients
6. MAP Pharmaceuticals Announces All Non-Asthmatic Patients Complete Treatment in Open-Label Trial and Completion of Treatment in QT Trial for LEVADEX™ Clinical Program
7. First AXL1717 Clinical Data From Ongoing Phase I/II Study in Cancer Patients has Been Published
8. Webmedx Strengthens Quality Program and Improves Patient Safety in Compliance with New Industry Standards for Clinical Documentation
9. Agensys, an Affiliate of Astellas, Announces Initiation of Phase I Clinical Trial of AGS-16M8F for Renal Cancer
10. Elbit Imaging Announces Insightec Treats First Prostate Cancer Patients in Clinical Trials
11. Morehead Memorial Hospital Goes Live with Thomson Reuters Clinical Xpert CareFocus
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2015)... , Israele, February 27, 2015 ... nel suo sviluppo dell,innovativo sistema di monitoraggio dell,infarto ... primo trial sull,uomo-     ... nello sviluppo di nuovo sistema per il monitoraggio ... (CHF), ha annunciato oggi di aver concluso una ...
(Date:2/27/2015)... Feb. 27, 2015 Isis Pharmaceuticals, Inc. (Nasdaq: ... both its pro forma net operating loss (NOL) guidance ... strong financial position.  Isis, significantly improved financial results were ... million in payments the Company received from its partners.  ... was a nearly 60% improvement over its 2013 NOL ...
(Date:2/27/2015)... , Feb. 27, 2015 An aggressive campaign ... cut the rate of infection with a dangerous drug-resistant ... Clostridium difficile, or C.diff, is a bacterium ... inflammation of the colon. A recent article in the ... difficile Infection in the United States ...
Breaking Medicine Technology:Vectorious Medical Technologies completa una raccolta di 5 milioni di dollari 2Isis Reports Financial Results and Highlights for 2014 2Isis Reports Financial Results and Highlights for 2014 3Isis Reports Financial Results and Highlights for 2014 4Isis Reports Financial Results and Highlights for 2014 5Isis Reports Financial Results and Highlights for 2014 6Isis Reports Financial Results and Highlights for 2014 7Isis Reports Financial Results and Highlights for 2014 8Isis Reports Financial Results and Highlights for 2014 9Isis Reports Financial Results and Highlights for 2014 10Isis Reports Financial Results and Highlights for 2014 11Isis Reports Financial Results and Highlights for 2014 12Isis Reports Financial Results and Highlights for 2014 13Isis Reports Financial Results and Highlights for 2014 14Isis Reports Financial Results and Highlights for 2014 15Isis Reports Financial Results and Highlights for 2014 16Isis Reports Financial Results and Highlights for 2014 17Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 2Curb Overuse Of Antibiotics To Reduce Drug-Resistant Superbug 3
... , KRX-0401 + Capecitabine More Than Doubles Time ... Overall Survival vs. Capecitabine + Placebo in Patients with ... NEW YORK, June 1 Keryx Biopharmaceuticals, Inc. (Nasdaq: ... of KRX-0401 (perifosine), the Company,s Akt-inhibitor for cancer, in combination ...
... GATESHEAD, England, June 1 A leading GP has ... around the world the hope of combating the killer disease. , ... of Ateronon, the natural supplement,developed by Cambridge scientists, was a huge ... heart attacks and stroke. , Dozens of ...
Cached Medicine Technology:Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 2Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 3Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 4Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 5Keryx Biopharmaceuticals Announces Positive Data from a Randomized, Multi-Center, Placebo-Controlled, Phase 2 Combination Study of KRX-0401 (Perifosine) in the Treatment of Advanced Metastatic Colon Cancer 6Heart Disease Treatment Breakthrough 2Heart Disease Treatment Breakthrough 3
(Date:2/28/2015)... February 28, 2015 In a recent ... of Game Change Athlete Development Services ... about the benefits of athlete development and player engagement ... the unique challenges that athletes face and how off-field ... success. , Fletcher became involved in athlete development issues ...
(Date:2/28/2015)... The Heart Fit Clinic started doing External Counterpulsation ... The Heart Fit Clinic is also selling the machines ... The goal is to scale the business to help ... buy External Counterpulsation machines can be difficult process. ... process and achieve the desired results. , The ...
(Date:2/28/2015)... February 28, 2015 Mew and Company, ... that they now provide business consulting services in addition ... corporate tax planning and succession planning. Company finances are ... experienced professionals. On top of this, complex Canadian tax ... corporate accounting. As a result, Mew and Company works ...
(Date:2/28/2015)... A study out of the University of Oxford ... the treatment of a hereditary ocular condition that leads ... Dr. Robert MacLaren, professor of ophthalmology at the University ... on January 16, 2014 , the study treated six ... mostly affects men and leads to the degeneration of ...
(Date:2/28/2015)... OR (PRWEB) February 28, 2015 Pioneer ... the 2015 Japan Architecture & Construction Materials Show, an ... join more than 1,000 suppliers and top manufacturers of ... Reclaimed wood products sourced and manufactured by ... have found popularity in Japan at restaurants, hotels, retailers, ...
Breaking Medicine News(10 mins):Health News:SCI TV Covers Athlete Development with Duncan Fletcher 2Health News:SCI TV Covers Athlete Development with Duncan Fletcher 3Health News:Clinicians Can Now Purchase External Counterpulsation with Heart Fit Clinic 2Health News:Vancouver Corporate Tax Accountants Now Provide Business Consulting Services 2Health News:New Gene Therapy Procedure Could Hold Key to Preventing Blindness for Certain Patients 2Health News:US Reclaimed Wood from Pioneer Millworks to be Featured at Architecture & Construction Materials Show in Tokyo. 2
... developed for preventing and treating the flue have shown ... dose to be effective.// The compounds, known collectively as ... relenza, or zanamivir, which the U.S. Food and Drug ... B. ,Researchers reported at the International Conference on ...
... to be worrisome threats, common pest control agent called ... treatments in eradicating deadly bacterial spores from buildings. Tests ... 50 years to control insect pests in buildings, grain ... than current treatments such as chlorine dioxide for killing ...
... giant GlaxoSmithKline (GSK), under fire regarding its smoking cessation drug, ... - in the wake of unproven reports in the UK, ... , ,Touted to be the world’s most successful smoking cessation ... June 2001. The cause for concern, however, was a safety ...
... University Hospital, a common cholesterol fighting drug, a statin ... heart complications by up to 20 percent for about ... heart events -- such as dying of heart disease ... Dr. Patrick Serruys,// professor of interventional cardiology at Erasmus ...
... the Marquette University School of Dentistry suggest chronic periodontal ... diabetes.//The research ties the incidence of diabetes in patients ... the bloodstream that triggers a reaction from the immune ... release proteins called cytokines that can disrupt production of ...
... University of Texas in US have found that African American ... women.// Ovarian cancer causes more deaths than any other cancer ... ethnicity is an independent risk factor in prognosis. US researchers ... 600 African American women with ovarian cancer. They find that ...
Cached Medicine News:Health News:Cholesterol Drug Helps After Angioplasty 2Health News:Cholesterol Drug Helps After Angioplasty 3
... Series Spectrophotometer is truly ... UV-VIS instrumentation. The latest ... into a radically new ... and performance unprecedented in ...
... Colony Counter allows the user to quickly and ... allows for digital counting or manual counting. An ... lens increasing magnification to 3.0X. The adjustable focusing ... raised or lowered. The lens also rotates a ...
... Quebec Colony Counter allows the user to quickly ... models allows for digital counting or manual counting. ... standard lens increasing magnification to 3.0X. The adjustable ... be raised or lowered. The lens also rotates ...
The Accucount 1000 is designed to automatically count macroscopic objects in a field displaying totals on a highly visible digital readout....
Medicine Products: